

# PRIOR AUTHORIZATION CRITERIA

<b>BRAND NAME</b> (generic)	<b>APRETUDE</b> (cabotegravir extended-release injectable suspension)
--------------------------------	--

*Status:*

## FDA-APPROVED INDICATION

Apretude is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.

## CRITERIA FOR APPROVAL

Is the requested drug prescribed for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus-1 (HIV-1) infection?  
[If no, then no further questions.]

----AND----

Does the patient weigh at least 35 kilograms (kg)?  
[If no, then no further questions.]

----AND----

Prior to initiating therapy, does the patient have a negative human immunodeficiency virus-1 (HIV-1) test?

----AND----

Trial and failure, contraindication or intolerance to BOTH of the following:

- emtricitabine-tenofovir (generic Truvada)
- Descovy

-----OR-----

Submission of medical records (e.g., chart notes) from provider documenting BOTH of the following:

- Patient would benefit from long-acting injectable therapy over standard oral regimens
- Patient would be adherent to testing and dosing schedule

Approval duration: 12 months